Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 30.1% in December

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 549,299 shares, an increase of 30.1% from the November 30th total of 422,094 shares. Currently, 1.5% of the company’s shares are short sold. Based on an average daily trading volume, of 97,160 shares, the short-interest ratio is currently 5.7 days. Based on an average daily trading volume, of 97,160 shares, the short-interest ratio is currently 5.7 days. Currently, 1.5% of the company’s shares are short sold.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in EPRX. Royal Bank of Canada increased its position in shares of Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after acquiring an additional 59,683 shares in the last quarter. Ingalls & Snyder LLC acquired a new stake in Eupraxia Pharmaceuticals in the 2nd quarter valued at $214,000. JPMorgan Chase & Co. raised its position in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at about $61,000. Finally, Bank of America Corp DE raised its holdings in shares of Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares during the period.

Eupraxia Pharmaceuticals Stock Performance

Eupraxia Pharmaceuticals stock remained flat at $7.73 during mid-day trading on Tuesday. The company’s stock had a trading volume of 16,627 shares, compared to its average volume of 54,201. The stock has a market capitalization of $277.97 million, a price-to-earnings ratio of -8.89 and a beta of 1.38. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $8.00. The stock has a fifty day moving average price of $6.18 and a 200-day moving average price of $5.67.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. Sell-side analysts predict that Eupraxia Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EPRX has been the topic of several research analyst reports. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eupraxia Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $11.67.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.